Personalized drug screening for glioblastoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to treat patients with newly diagnosed glioblastoma by identifying effective personalized drug regimens through high-throughput screening of cancer stem cells derived from their tumors. A panel of FDA-approved drugs will be tested to find a combination of up to three candidates that can be used alongside standard chemoradiation therapy. The selected drug candidates will be evaluated for safety and efficacy by a team of pharmacists and physicians before treatment initiation. This approach seeks to enhance treatment outcomes by tailoring therapies to individual patient profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological diagnosis of GBM (WHO grade 4)
* Subjects ≥18 years of age
* Patients must have a life expectancy of \>6 months
* Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)
* Patients must have a KPS rating of ≥70
* Patients should not have received any prior systemic anti-cancer therapy
* Patients must be negative for HIV, Hepatitis B and C
* Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:

  * Hemoglobin (Hgb)\> 8 g/dL
  * Absolute Neutrophil Count (ANC) \> 1,000/mm3
  * Platelet count \> 100,000/mm3
  * Creatinine \< 2 mg/dL
  * Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \< 3x upper limit of normal (ULN)

Exclusion Criteria:

* Metastatic disease
* Diseases or conditions that obscure toxicity or dangerously alter drug metabolism
* Serious intercurrent medical illness
* Inadequately controlled hypertension
* History of myocardial infarction or unstable angina within 6 months
* History of stroke or transient ischemic attack within 6 months

Where it's running

• Swedish Medical Center
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Charles S Cobbs — Ivy Center for Advanced Brain Tumor Treatment
• Study coordinator: Charles S Cobbs, M.D.
• Email: charles.cobbs@swedish.org
• Phone: 206-320-2300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maintenance radiotherapy after standard glioblastoma treatment

  This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07831772

• AAV dual-payload gene therapy injected directly into high-grade glioma to kill tumor cells and stimulate immune attack.

  This will try TGX-007, a virus-delivered gene therapy given into the tumor together with oral valaciclovir, in adults 18–70 with newly diagnosed or recurrent glioblastoma to see if it safely kills tumor cells and boosts immune response.

  Recruiting at 2 sites Phase 1/2 Trogenix ltd · Columbus, Ohio and 1 other locations · NCT07346144

• Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII

  This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.

  Recruiting at 38 sites Phase 2 Black Diamond Therapeutics, Inc. · Birmingham, Alabama and 37 other locations · NCT07326566

• Anterior (front) temporal lobe removal for temporal glioblastoma

  This will see if removing the front part of the temporal lobe (anterior temporal lobectomy) helps people with newly diagnosed temporal-lobe glioblastoma live longer than standard complete tumor removal (gross-total resection).

  Recruiting Phase 3 University Hospital, Bonn · Bonn, North Rhine-Westphalia · NCT07021339

• Nivolumab with or without relatlimab for newly diagnosed IDH‑wildtype glioblastoma

  This trial will test whether giving nivolumab alone or together with relatlimab around surgery helps adults with newly diagnosed IDH‑wildtype glioblastoma.

  Recruiting at 4 sites Phase 2 Duke University · New York, New York and 3 other locations · NCT06816927

• New cancer vaccine for glioblastoma patients

  This study is testing a new cancer vaccine for people with newly diagnosed glioblastoma to see if it can help boost their immune response after standard treatment.

  Recruiting at 2 sites Phase 1/2 Assistance Publique - Hôpitaux de Paris · Paris, Idf and 2 other locations · NCT06622434

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.